Lantheus Acquires Meilleur Technologies (NAV-4694)

Lantheus Holdings Acquires Cerveau Technologies

February 6, 2023

Pharmaceuticals

Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.

Lantheus Acquires Life Molecular Imaging from Life Healthcare

July 22, 2025

Healthcare Services

Lantheus Holdings, Inc. completed the acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd., gaining the Neuraceq (florbetaben F18) commercial product, expanded Alzheimer’s radiodiagnostic infrastructure, and additional R&D capabilities. As part of the transaction, Dr. Ludger Dinkelborg (formerly CEO of Life Molecular) will join Lantheus as Head of Research & Development, reporting to the CEO.

SHINE Technologies Acquires Lantheus' SPECT Business

January 2, 2026

Pharmaceuticals

SHINE Technologies has completed the acquisition of Lantheus' SPECT business, including the North Billerica, Massachusetts SPECT manufacturing facility and a portfolio of diagnostic radiopharmaceuticals (TechneLite, Cardiolite, NEUROLITE, Xenon Xe-133). SHINE named Michael Rossi CEO of SHINE SPECT USA, LLC and said the acquisition expands its nuclear medicine manufacturing capabilities and integrates with its Chrysalis Mo-99 production to strengthen isotope supply chain security.

AbbVie Acquires Aliada Therapeutics for $1.4 Billion

December 11, 2024

Biotechnology

AbbVie has completed the $1.4 billion acquisition of Aliada Therapeutics, a RA Capital- and JJDC-backed biotech developing ALIA-1758, an anti‑pyroglutamate amyloid beta antibody that uses a blood‑brain‑barrier crossing technology for Alzheimer's disease. The deal brings Aliada's CNS drug‑delivery platform and lead Phase 1 asset into AbbVie's neuroscience pipeline and represents an exit for RA Capital's Raven incubator and other early investors.

Inhance Technologies Acquires Fluor Technik System GmbH

October 16, 2019

Manufacturing

Inhance Technologies, a portfolio company of Aurora Capital Partners, has acquired Fluor Technik System GmbH (FTS), a Lauterbach-based provider of post-mold fluorination and plastic surface modification solutions. The acquisition gives Inhance a strategic European presence and expands its fluorination capabilities to better serve customers across medical devices, consumer products, automotive and other end markets.

Full-Life Technologies Acquires Focus‑X Therapeutics

November 28, 2022

Biotechnology

Full‑Life Technologies, a global radiotherapeutics company, agreed to acquire New Jersey‑based Focus‑X Therapeutics to expand its peptide‑focused radiopharmaceutical pipeline. Focus‑X shareholders are eligible for an upfront payment plus up to $245 million in development, regulatory and sales milestones and royalties; the deal was expected to close in Q1 2023.